News
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts. On July 10, REGENXBIO ...
Amazon S3 on MSN2d
The story of Sarepta's Duchenne gene therapy
The last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
The European drug authority recommends refusal of marketing authorization after study shows no benefit over placebo.
MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has announced the launch of myMDteam. This new website and patient community is ...
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular ...
Genethon is determined to bring GNT0004 to market for young patients and their families who are waiting for a therapeutic ...
Lancashire Evening Post on MSN2d
Cumbria family’s ‘Iron Will’ triathlon for son living with muscular dystrophy
On Thursday 28 August, Sam Taylor, 46, his wife Sue, 47, and daughter Beth, 17, from Crooklands in Cumbria will set off to ...
Genetic testing could not confirm Duchenne muscular dystrophy, but a muscle biopsy at UCLA did. "He could see that he was ...
European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...
Monday, the FDA said Sarepta may resume treating ambulatory DMD patients with Elevidys. The recommendation comes just 10 days ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback